Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Recommendation of “Hold” by Brokerages

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have earned an average rating of “Hold” from the twenty-two brokerages that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $124.15.

ZBH has been the topic of several recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Truist Financial reaffirmed a “hold” rating and issued a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Stifel Nicolaus boosted their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Raymond James decreased their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Finally, Barclays dropped their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Monday, February 10th.

Zimmer Biomet Stock Up 1.4 %

NYSE:ZBH opened at $112.20 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The stock has a market capitalization of $22.34 billion, a P/E ratio of 25.21, a P/E/G ratio of 1.95 and a beta of 1.04. The company’s 50-day simple moving average is $107.13 and its 200-day simple moving average is $106.96. Zimmer Biomet has a fifty-two week low of $97.69 and a fifty-two week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the company earned $2.20 EPS. On average, equities analysts anticipate that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. Zimmer Biomet’s payout ratio is currently 21.57%.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.95% of the company’s stock.

Institutional Trading of Zimmer Biomet

Large investors have recently added to or reduced their stakes in the stock. Stonebridge Financial Group LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter valued at about $25,000. Dunhill Financial LLC boosted its holdings in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares during the last quarter. Menard Financial Group LLC acquired a new position in Zimmer Biomet in the 4th quarter valued at about $30,000. Brooklyn Investment Group purchased a new stake in shares of Zimmer Biomet in the 3rd quarter valued at approximately $35,000. Finally, Accredited Wealth Management LLC acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $36,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.